<DOC>
	<DOCNO>NCT02544932</DOCNO>
	<brief_summary>Atrial fibrillation ( AF ) know several pathophysiologic mechanism include endothelial dysfunction heart vessel . This study design determine efficacy NOAC therapy prevention endothelial dysfunction progression atherosclerosis AF subject .</brief_summary>
	<brief_title>Pleotropic Effect New Oral Anticoagulants</brief_title>
	<detailed_description>The property oral , direct inhibitor factor Xa ( e.g . rivaroxaban ) thrombin ( e.g . dabigatran ) examine haemostasis thromboembolism management . Preclinical study provide evidence effect direct factor Xa thrombin inhibition beyond anticoagulation , include anti-inflammatory protective activity atherosclerotic plaque development . Therefore , study evaluates protective effect NAOC reactive hyperemia peripheral arterial tonometry ( RH-PAT ) measurement reflect endothelial function Endo-PAT2000 intima-media thickness ( IMT ) carotid artery , use surrogate endpoint atherosclerosis .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>CHA2DS2VASc score 2 severe peripheral arterial disease ( great Fontaine IIb category ) grade 4 high cerebral infarction Modified Rankin Scale proven coronary artery disease coronary angiogram severe hepatic renal dysfunction uncontrolled congestive heart failure uncontrolled hypertension diabetes mellitus hematologic disorder allergy hypersensitivity investigational drug pregnant lactate woman woman wish become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>anticoagulant</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>endothelium</keyword>
</DOC>